NCT04888429View on ClinicalTrials.gov

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

December 30, 2024

Study Completion Date

June 30, 2025

Conditions
Sarcomatoid Carcinoma of Lung
Interventions
DRUG

Camrelizumab

Patients received camrelizumab 200 mg every 3 weeks

DRUG

Famitinib

Patients received Famitinib 20 mg once per day

Trial Locations (8)

430000

RECRUITING

Qian Chu, Wuhan

Unknown

ACTIVE_NOT_RECRUITING

The first Affiliated Hospital of Xiamen University, Xiamen

RECRUITING

Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou

RECRUITING

Henan Provincial People's Hospital, Zhengzhou

RECRUITING

Hubei Cancer Hospital, Wuhan

RECRUITING

Renmin Hospital of Wuhan University Hubei General Hospital, Wuhan

RECRUITING

The Second Xiangya Hospital of Central South University, Changsha

ACTIVE_NOT_RECRUITING

The First Affiliated Hospital of Shandong First Medical University, Jinan

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Qian Chu

OTHER